CC49 murine radioimmunoconjugates (National Cancer Institute)

N/A

Report date: 2025/10/20 14:43:37

Base Information

Drug NameCC49 murine radioimmunoconjugates (National Cancer Institute)
Drug Alias Name90Y-CC4990Yttrium-CC49
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionTumor-associated glycoprotein 72 binders
TargetsTumor-associated glycoprotein 72
Therapy Area/IndicationsOvarian NeoplasmsAbdominal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Alabama At BirminghamNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNational Cancer InstituteUniversity Of Alabama At Birmingham
Active IndicationsN/A
Inactive IndicationsOvarian NeoplasmsAbdominal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A